Physician profile
Thomas M Brown
NPI 1528066461
$5,331.90
in general payments reported to CMS, 2019-2025
24 companies · $624 in 2025
The $624 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,261 · 2020: $103 · 2021: $540 · 2022: $583 · 2023: $732 · 2024: $488 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,305.18 | 2019-2025 | Mitraclip |
| Boston Scientific Corporation | $1,057.74 | 2019-2024 | Watchman Flx, Varithena Administration Pack |
| Novartis Pharmaceuticals Corporation | $537.77 | 2019-2025 | |
| Amgen INC. | $337.98 | 2019-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $310.57 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $181.15 | 2021-2025 | Brilinta, Andexxa |
| Bayer Healthcare Pharmaceuticals INC. | $166.45 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $166.04 | 2023-2024 | Opsumit, Uptravi |
| Medtronic Vascular, INC. | $156.93 | 2019-2020 | |
| Medtronic, INC. | $146.72 | 2022 | |
| Janssen Pharmaceuticals, INC | $138.96 | 2019-2024 | Xarelto |
| Pfizer INC. | $137.25 | 2019-2025 | |
| Cardiovascular Systems INC. | $120.33 | 2019 | |
| Scpharmaceuticals INC. | $113.35 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.52 | 2019-2025 | Lifevest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $71.74 | 2019-2023 | Camzyos |
| Sanofi-Aventis U.S. LLC | $66.18 | 2019-2021 | |
| Inspire Medical Systems, INC. | $54.41 | 2024 | Inspire |
| Novo Nordisk INC | $46.51 | 2025 | Wegovy |
| Lundbeck LLC | $36.03 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $34.52 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $24.26 | 2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.68 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $22.63 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.